CLINICOPATHOLOGICAL CHARACTERISTICS OF 38 PATIENTS WITH STAGE I HIGH-GRADE SEROUS OVARIAN CANCER WHO RECEIVED ADJUVANT CHEMOTHERAPY

Year 2022, Volume: 23 Issue: 3, 335 - 338, 18.07.2022

Caner Çakır Rıza Dur Betül Tokgöz Doğukan Özkan Çağatayhan Öztürk Fulya Kayıkçıoğlu Vakkas Korkmaz

https://doi.org/10.18229/kocatepetip.943572

Abstract

OBJECTIVE: Epithelial ovarian cancer is the most mortal among female cancers and is mostly diagnosed at an advanced stage It was aimed to investigate the clinicopathological features and recurrence patterns of patients who were diagnosed with stage 1 high-grade serous ovarian cancer and received adjuvant chemotherapy after surgery.
MATERIAL AND METHODS: Thirty-eight high-grade serous ovarian cancer patients treated in our clinic, stage 1 patient who underwent total abdominal hysterectomy + bilateral salpingooferectomy + pelvic-paraaortic lymph node dissection +/- omentectomy were included in the study.
RESULTS: Regarding the stage distribution of the patients, Stage IA 10 patients (26.3%), IB 7 patients (18.4), IC1 5 patients (13.2%), IC2 11 patients (28.9%), IC3 5 patients (13%) , 2). Recurrence developed in 11 (28.9%) of 38 patients. Regarding the recurring regions of the patients with recurrence, only pelvic 1 (2.6%), only the abdomen 8 (21.1%), while abdominal + pelvic recurrence developed in 1 (2.6) patient.
CONCLUSIONS: Serous histology is the most common subgroup of epithelial ovarian cancers and usually diagnosed at an advanced stage. The relapse rate is also high in patients diagnosed at an early stage.

Keywords

Serous ovarian cancer, Early stage, Recurrence.

ADJUVANT KEMOTERAPİ ALMIŞ EVRE I YÜKSEK DERECELİ SERÖZ OVER KANSERİ OLAN 38 HASTANIN KLİNİKOPATOLOJİK ÖZELLİKLERİ

Abstract

AMAÇ: Epitelyal over kanseri kadın kanserleri arasında en mortal olan olup çoğunlukla ileri evrede tanı almaktadır. Evre I high-grade seröz over kanseri tanısı alan ve cerrahi sonrasında adjuvant kemoterapi alan hastaların klinikopatolojik özellikleri ve nüks paternlerinin araştırılması amaçlanmıştır.
GEREÇ VE YÖNTEM: Kliniğimizde tedavi görmüş olan 38 high-grade seröz over kanseri nedeniyle total abdominal histerektomi+bilateral salfingooferektomi+pelvik-paraaortik lenf nodu diseksiyon +/- omentektomi yapılan evre I hasta çalışmaya dahil edilmiştir.
BULGULAR: Hastaların evre dağılımına bakıldığında Evre IA 10 hasta (%26,3), IB 7 hasta (18,4), IC1 5 hasta (%13,2), IC2 11 hasta (%28,9), IC3 5 hasta (% 13,2) idi. 38 hastanın 11’inde (%28,9) rekürrens gelişti. Rekürrens gelişen hastaların nüks gelişen bölgelere bakıldığında sadece pelvik 1 (%2,6), sadece abdomen 8 (%21,1) iken abdominal + pelvik nüks 1 (2,6) hastada gelişti.
SONUÇ: Epitelyal over kanserleri arasında en sık görülen alt grup seröz histolojidir ve genelde ileri evrede tanı alırlar. Erken evrede tanı alan alan hastalarda da nüks oranı yüksektir.

Keywords

Seröz overyan kanser, Erken evre, Rekürrens.

References

• 1. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1-5.
• 2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;15;127(12):2893-917.
• 3. Torre LA, Trabert B, DeSantis CE et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296.
• 4. Jang JYA, Yanaihara N, Pujade-Lauraine E, et al. Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. J Gynecol Oncol. 2017;28(4):e54.
• 5. Ye S, Yang J, You Y, et al. Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients. PLoS One. 2015;10(7):e0133498.
• 6. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014; 133: 401–4.
• 7. WHO handbook for reporting results of cancer treatment. 1979.
• 8. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4):259.
• 9. Anglesio MS, Carey MS, Kobel M, et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 2011;121(2):407-15.
• 10. Bahadır Saatli, Turab Janbakhisov, Özlen Emekçi ve ark. Peritoneal karsinomatoza bulgusu olmayan çok yüksek serum CA 125 değeri olan adneksiyal kitlelerin klinikopatolojik değerlendirilmesi, Dokuz Eylül Tıp Fakültesi Dergisi. 2013;27(1):33-38.
• 11. Duygu Güzel, Nuri Yıldırım, Ayşegül Dikmen ve ark. Over kanserinin epidemiyolojisi ve genel sağ kalım özellikleri. Ege Tıp Dergisi. 2019;58: 44-49.
• 12. Serap Erben Durmuşoğlu, Fatih Kılıç, Mehmet Ünsal ve ark. Preoperatif Nötrofil/Lenfosit, Lenfosit/Monosit ve Trombosit/Lenfosit Oranlarının Seröz Over Kanseri Sağ Kalımındaki Yeri. Balıkesir Medical Journal. 2021;5(1): 43-53.
• 13. I. Vergote, J. De Brabanter, A. Fyles, et al. , Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176-82 176–82.
• 14. J.K. Chan, C. Tian, B.J. Monk, et al. Prognostic factors for high-risk earlystage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008;112(10):2202-10.
• 15. Amate P, Huchon C, Dessapt AL, et al. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013;23(9):1590-6.